Treatment News : High HCV Cure Rates for BMS Set Stage for Triple Combo Pill

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 10, 2014

High HCV Cure Rates for BMS Set Stage for Triple Combo Pill

CROI 2014Twelve weeks of Bristol-Myers Squibb’s daclatasvir, asunaprevir and BMS-791325 (’325) cured more than nine out of 10 treatment-naive people with genotype 1 of hepatitis C virus in a recent study, MedPage Today reports. The results open the door for research of a triple-drug combination pill. Results from the randomized, Phase IIb open-label trial were presented at the Conference on Retroviruses and Opportunistic Infections (CROI).

The trial was divided into two groups of participants who received 12 weeks of the NS5A inhibitor daclatasvir, the protease inhibitor asunaprevir and the non-nucleoside ’325. In one group of 80 people, ’325 was dosed at 75 milligrams twice a day, and in another group of 86 people, the drug’s dose was doubled.

Two people discontinued therapy because of adverse side effects. Eleven people experienced virologic failure. The investigators concluded that the only factor that made virologic failure more likely was having genotype 1a of the virus rather than 1b.

Out of the participants for whom the researchers had final data, 92.2 percent (71 out of 77) of those taking the lower dose of ’325 achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure) and 91.7 percent (77/84) of those receiving the higher dose achieved an SVR12.

The investigators found that the results of the trial supported the UNITY 1 and UNITY 2 Phase III trials of a twice-daily fixed dose combination pill of all three drugs, with ’325 at the lower dose.

To read the MedPage Today story, click here.

Search: Bristol Myers Squibb, daclatasvir, asunaprevir, BMS-791325, Conference on Retroviruses and Opportunistic Infections, CROI, UNITY 1, UNITY 2, hepatitis C


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    charliehunter
    San Francisco
    California


    Loveladyd
    Washington
    DC


    cortaza100
    Chicago
    Illinois


    daino1972
    Columbus
    Ohio
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.